Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2".
作者信息
Du Yin-Xiao, Chen Xiao-Ping
机构信息
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, Hunan, China.
出版信息
Clin Pharmacol Ther. 2020 Aug;108(2):190. doi: 10.1002/cpt.1878. Epub 2020 May 21.
Abstract
摘要
相似文献
1
Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2".对“法匹拉韦用于感染严重急性呼吸综合征冠状病毒2患者的剂量依据”的回应
Clin Pharmacol Ther. 2020 Aug;108(2):190. doi: 10.1002/cpt.1878. Epub 2020 May 21.
2
Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2.法匹拉韦用于感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）患者的剂量依据。
Clin Pharmacol Ther. 2020 Aug;108(2):188. doi: 10.1002/cpt.1877. Epub 2020 May 21.
3
Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).非那韦和对 SARS-CoV-2 感染（COVID-19）早期门诊治疗的需求。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.02017-20.
4
Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence.基于现有证据探讨法匹拉韦在新冠疫情中的潜在新用途。
Travel Med Infect Dis. 2020 May-Jun;35:101710. doi: 10.1016/j.tmaid.2020.101710. Epub 2020 Apr 28.
5
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.新型冠状病毒肺炎患者使用甲磺酸萘莫司他和法匹拉韦治疗的相关不良事件。
Crit Care. 2020 Aug 12;24(1):497. doi: 10.1186/s13054-020-03227-4.
6
Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.口服法匹拉韦治疗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒RNA清除延迟患者：病例系列
Crit Care. 2020 Sep 25;24(1):578. doi: 10.1186/s13054-020-03288-5.
7
A Favipiravir-induced Fever in a Patient with COVID-19.一名新冠肺炎患者出现法匹拉韦诱发的发热
Intern Med. 2020;59(22):2951-2953. doi: 10.2169/internalmedicine.5394-20. Epub 2020 Nov 15.
8
Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019.在使用法匹拉韦治疗冠状病毒病2019期间发生的急性痛风性关节炎
Intern Med. 2020 Sep 15;59(18):2327-2329. doi: 10.2169/internalmedicine.5377-20. Epub 2020 Jul 28.
9
Favipiravir, an antiviral for COVID-19?法匹拉韦，一种用于治疗新冠肺炎的抗病毒药物？
J Antimicrob Chemother. 2020 Jul 1;75(7):2013-2014. doi: 10.1093/jac/dkaa171.
10
Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.关于法匹拉韦重新用于对抗新型冠状病毒的系统评价。
Mymensingh Med J. 2020 Jul;29(3):747-754.
引用本文的文献
1
A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.一种测定人外周血单个核细胞中法匹拉韦核糖呋喃核苷酸-5'-三磷酸（T-705-RTP）的新型 LC-MS/MS 方法。
J Pharm Biomed Anal. 2024 Aug 1;245:116155. doi: 10.1016/j.jpba.2024.116155. Epub 2024 Apr 21.
2
Development and validation of method for analysis of favipiravir and remdesivir in volumetric absorptive microsampling with ultra high-performance liquid chromatography-tandem mass spectrophotometry.超高效液相色谱-串联质谱法在体积吸收微采样中分析法匹拉韦和瑞德西韦的方法开发与验证
Front Med (Lausanne). 2023 May 5;10:1022605. doi: 10.3389/fmed.2023.1022605. eCollection 2023.
3
Novel Antiviral Activity of Ethyl 3-Hydroxyhexanoate Against Coxsackievirus B Infection.3-羟基己酸乙酯对柯萨奇病毒B感染的新型抗病毒活性
Front Microbiol. 2022 Apr 14;13:875485. doi: 10.3389/fmicb.2022.875485. eCollection 2022.
4
The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.新冠病毒的历史、疗效和安全性：对 COVID-19 复杂生命的叙事概述。
Int J Environ Res Public Health. 2021 Jan 22;18(3):955. doi: 10.3390/ijerph18030955.
5
Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19.了解法匹拉韦的药代动力学：对流感和COVID-19治疗的意义。
EBioMedicine. 2021 Jan;63:103204. doi: 10.1016/j.ebiom.2020.103204. Epub 2021 Jan 6.
6
Role of favipiravir in the treatment of COVID-19.法匹拉韦在治疗 COVID-19 中的作用。
Int J Infect Dis. 2021 Jan;102:501-508. doi: 10.1016/j.ijid.2020.10.069. Epub 2020 Oct 30.
7
Favipiravir use for SARS CoV-2 infection.用于治疗 SARS-CoV-2 感染的法匹拉韦。
Pharmacol Rep. 2020 Dec;72(6):1542-1552. doi: 10.1007/s43440-020-00175-2. Epub 2020 Oct 27.
8
The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19).血红素加氧酶 1（HMOX1）通路作为 2019 年新型冠状病毒（COVID-19，即 SARS-CoV-2）治疗和预防的有前途靶点。
Int J Mol Sci. 2020 Sep 3;21(17):6412. doi: 10.3390/ijms21176412.
9
Novel β-Coronavirus (SARS-CoV-2): Current and future aspects of pharmacological treatments.新型β冠状病毒（严重急性呼吸综合征冠状病毒2）：药物治疗的现状与未来展望
Saudi Pharm J. 2020 Oct;28(10):1243-1252. doi: 10.1016/j.jsps.2020.08.015. Epub 2020 Aug 27.
10
Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.对 COVID-19 感染新治疗领域的药代动力学（PK）和药代动力学-药效学（PK-PD）研究的关注。
Antiviral Res. 2020 Sep;181:104866. doi: 10.1016/j.antiviral.2020.104866. Epub 2020 Jul 10.
本文引用的文献
1
Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2.法匹拉韦用于感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）患者的剂量依据。
Clin Pharmacol Ther. 2020 Aug;108(2):188. doi: 10.1002/cpt.1877. Epub 2020 May 21.
2
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.瑞德西韦、洛匹那韦、依米丁和高三尖杉酯碱在体外抑制 SARS-CoV-2 复制。
Antiviral Res. 2020 Jun;178:104786. doi: 10.1016/j.antiviral.2020.104786. Epub 2020 Apr 3.
3
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.法匹拉韦：药代动力学与对 2019 新型冠状病毒感染临床试验的关注。
Clin Pharmacol Ther. 2020 Aug;108(2):242-247. doi: 10.1002/cpt.1844. Epub 2020 Apr 21.
4
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
Zotero 插件